Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0873 · 1 trial · 1 indication
Swollen joint count (SJC) was determined by assessing 66 joints (33 right side, 33 left side) for swelling using the following grading system: 0=Absent, 1=Detectable synovial thickening without loss of bony contours, 2=Loss of distinctiveness of bony contours, or 3=Bulging synovial proliferation with cystic characteristics. The total number of joints graded 1, 2, or 3 were then counted to yield the SJC. SJC ranged from 1-66, with increasing score indicating greater number of swollen joints. SJC was averaged over weeks 8, 10 and 12 to yield a Treatment Period Mean. Change from Baseline = Treatment Period Mean SJC - Baseline SJC.
| Arm | Type | Description |
|---|---|---|
| MK-0873 | EXPERIMENTAL | MK-0873 1.25 mg twice daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| MK-0873 | DRUG | MK-0873 1.25 mg twice daily for 12 weeks |
| Comparator: Placebo | DRUG | Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks |
Inclusion Criteria: * Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications * Other criteria also apply Exclusion Criteria: * Other major illnesses * Past history of certain other disorders * Certain prohibited medication...
Top 20 of 28 competitors
MK-0873 is an investigational small molecule being studied for rheumatoid arthritis and plaque psoriasis. It is being developed by Merck & Company, Inc. (MRK). The drug has completed a Phase 2 trial in rheumatoid arthritis and a Phase 1 trial in plaque psoriasis, but it is not approved and remains in clinical development.
MK-0873 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company has sponsored clinical trials of the drug in rheumatoid arthritis and plaque psoriasis.
MK-0873 is in Phase 2 clinical development. A Phase 2 trial in rheumatoid arthritis has been completed, and a Phase 1 trial in plaque psoriasis has also been completed. The drug is investigational and not approved.
MK-0873 has been studied in two completed trials. NCT00132769 was a Phase 2, randomized, double-blind, placebo-controlled study in 106 rheumatoid arthritis patients. NCT01140061 was a Phase 1 study in 42 healthy participants and psoriasis participants.
MK-0873 is the code name used by Merck for this investigational compound. No alternative brand or generic names have been disclosed in the clinical trial records.